The price ain’t right: Lilly

Positive funding recommendation for Mounjaro came with “unviable and unsustainable conditions”, sponsor says  Eli Lilly is calling for “wholesale changes" to be made to the PBS (Pharmaceutical Benefits Scheme) after withdrawing its application to have Mounjaro (tirzepatide) listed.  The decision, announced on Friday, 24 April 2026, was the third time in 26 months that Eli Lilly has abandoned plans to list